JP2011517320A5 - - Google Patents

Download PDF

Info

Publication number
JP2011517320A5
JP2011517320A5 JP2010549831A JP2010549831A JP2011517320A5 JP 2011517320 A5 JP2011517320 A5 JP 2011517320A5 JP 2010549831 A JP2010549831 A JP 2010549831A JP 2010549831 A JP2010549831 A JP 2010549831A JP 2011517320 A5 JP2011517320 A5 JP 2011517320A5
Authority
JP
Japan
Prior art keywords
mmp
binding protein
human
binding
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2010549831A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011517320A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2009/035926 external-priority patent/WO2009111508A2/en
Publication of JP2011517320A publication Critical patent/JP2011517320A/ja
Publication of JP2011517320A5 publication Critical patent/JP2011517320A5/ja
Pending legal-status Critical Current

Links

JP2010549831A 2008-03-03 2009-03-03 メタロプロテアーゼ9結合タンパク質およびメタロプロテアーゼ2結合タンパク質 Pending JP2011517320A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US3306808P 2008-03-03 2008-03-03
US61/033,068 2008-03-03
PCT/US2009/035926 WO2009111508A2 (en) 2008-03-03 2009-03-03 Metalloproteinase 9 and metalloproteinase 2 binding proteins

Publications (2)

Publication Number Publication Date
JP2011517320A JP2011517320A (ja) 2011-06-02
JP2011517320A5 true JP2011517320A5 (enExample) 2012-04-26

Family

ID=41056616

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010549831A Pending JP2011517320A (ja) 2008-03-03 2009-03-03 メタロプロテアーゼ9結合タンパク質およびメタロプロテアーゼ2結合タンパク質

Country Status (6)

Country Link
US (2) US8013125B2 (enExample)
EP (1) EP2262840A4 (enExample)
JP (1) JP2011517320A (enExample)
AU (1) AU2009221916A1 (enExample)
CA (1) CA2717803A1 (enExample)
WO (1) WO2009111508A2 (enExample)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7745587B2 (en) 2005-12-30 2010-06-29 Dyax Corp. Antibodies that bind MMP-14
CA2707637A1 (en) 2007-12-17 2009-06-25 Dyax Corp. Compositions and methods for treating osteolytic disorders comprising mmp-14 binding proteins
WO2009079581A1 (en) * 2007-12-17 2009-06-25 Dyax Corp. Evaluating mmp expression in patient stratification and other therapeutic, diagnostic and prognostic methods for cancer
US8013125B2 (en) 2008-03-03 2011-09-06 Dyax Corp. Metalloproteinase 9 and metalloproteinase 2 binding proteins
JP2011517662A (ja) 2008-03-03 2011-06-16 ダイアックス コーポレーション メタロプロテアーゼ9結合タンパク質
WO2011028883A2 (en) * 2009-09-03 2011-03-10 Dyax Corp. Metalloproteinase 9 and metalloproteinase 2 binding proteins
US8530453B2 (en) * 2009-09-28 2013-09-10 Aquilus Pharmaceuticals, Inc. Compounds and methods for the treatment of pain and other diseases
CN102822202B (zh) 2010-01-27 2015-07-22 耶达研究及发展有限公司 抑制金属蛋白的抗体
CA2802376A1 (en) 2010-06-14 2011-12-22 Vaccinex, Inc. Anti-vegf antibodies and uses thereof
CA2839420C (en) 2010-06-16 2023-06-13 Lawrence M. Kauvar High affinity human antibodies to human cytomegalovirus (cmv) gb protein
WO2012027721A2 (en) 2010-08-27 2012-03-01 Gilead Biologics, Inc Antibodies to matrix metalloproteinase 9
WO2012054077A2 (en) * 2010-10-19 2012-04-26 Mayo Foundation For Medical Education And Research Human antibodies and diagnostic and therapeutic uses thereof for the treatment of neurological disease
WO2012129517A2 (en) * 2011-03-24 2012-09-27 Dyax Corp. Evaluating protein expression in patient stratification and other therapeutic, diagnostic and prognostic methods for cancer
US10314909B2 (en) 2011-10-21 2019-06-11 Dyax Corp. Combination therapy comprising an MMP-14 binding protein
SG11201405305PA (en) 2012-02-29 2014-09-26 Gilead Biologics Inc Antibodies to matrix metalloproteinase 9
MD20140108A2 (ro) 2012-02-29 2015-03-31 Gilead Biologics, Inc. Anticorpi împotriva metaloproteinazei 9 matriciale
US9732154B2 (en) 2014-02-28 2017-08-15 Janssen Biotech, Inc. Anti-CD38 antibodies for treatment of acute lymphoblastic leukemia
US9603927B2 (en) 2014-02-28 2017-03-28 Janssen Biotech, Inc. Combination therapies with anti-CD38 antibodies
EP2985295A1 (en) 2014-08-13 2016-02-17 Calypso Biotech SA Antibodies specific for MMP9
EP2985296A1 (en) 2014-08-13 2016-02-17 Calypso Biotech SA Antibodies specific for MMP9
WO2016040294A2 (en) 2014-09-09 2016-03-17 Janssen Biotech, Inc. Combination therapies with anti-cd38 antibodies
PE20171094A1 (es) 2014-12-04 2017-08-07 Janssen Biotech Inc Anticuerpos anti-cd38 para el tratamiento de la leucemia linfoblastica aguda
CR20170526A (es) 2015-05-20 2018-04-03 Janssen Biotech Inc ANTICUERPOS ANTI-CD38 PARA EL TRATAMIENTO DE AMILOIDOSIS DE CADENA LIGERA y OTRAS ENFERMEDADES MALIGNAS HEMATOLÓGICAS POSITIVAS PARA CD38
CN107708734B (zh) 2015-06-22 2022-01-11 詹森生物科技公司 用抗cd38抗体和生存素抑制剂联合治疗血红素恶性肿瘤
US20170044265A1 (en) 2015-06-24 2017-02-16 Janssen Biotech, Inc. Immune Modulation and Treatment of Solid Tumors with Antibodies that Specifically Bind CD38
US10781261B2 (en) 2015-11-03 2020-09-22 Janssen Biotech, Inc. Subcutaneous formulations of anti-CD38 antibodies and their uses
JP7027321B2 (ja) 2015-11-03 2022-03-01 ヤンセン バイオテツク,インコーポレーテツド 抗cd38抗体の皮下製剤及びその使用
US20200306283A1 (en) 2016-06-22 2020-10-01 William Warren HARLESS Cancer treatment and metastasis inhibition using an anti-cancer stem cell agent in combination with a neu1 sialidase inhibitor or a cytokine inhibitor after primary cancer treatment
WO2018002181A1 (en) 2016-06-28 2018-01-04 Umc Utrecht Holding B.V. TREATMENT OF IgE-MEDIATED DISEASES WITH ANTIBODIES THAT SPECIFICALLY BIND CD38
CN108456250B (zh) * 2017-02-17 2025-11-28 恺兴生命科技(上海)有限公司 靶向il-13ra2的抗体及其应用
WO2018169785A2 (en) * 2017-03-13 2018-09-20 The Government Of The United States Of America As Represented By The Secretary Of The Army Therapeutic antibodies to marburg virus
US11618787B2 (en) 2017-10-31 2023-04-04 Janssen Biotech, Inc. Methods of treating high risk multiple myeloma
EP3724657A4 (en) 2017-12-15 2021-12-29 Bomi, Llc Anti-cannabidiol antibody and uses thereof
CN110642948B (zh) * 2019-10-09 2021-06-29 达石药业(广东)有限公司 B7-h3纳米抗体、其制备方法及用途
CN121399157A (zh) 2023-06-12 2026-01-23 美国安进公司 淋巴毒素β受体激动剂结合蛋白
EP4788430A1 (en) 2023-10-05 2026-08-12 Ashibio, Inc. Methods and compositions for treating mmp-9 mediated disorders
WO2026076260A1 (en) 2024-10-03 2026-04-09 Ashibio, Inc. Methods and compositions for mmp-9 inhibition for use with non-genetic heterotopic ossification disorders

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9809764D0 (en) * 1998-05-07 1998-07-08 Isis Innovation MMP-9 Gene polymorphisms
ES2327812T3 (es) 1999-07-13 2009-11-04 University Of Southern California Nuevos metodos y composiciones para inhibir la angiogenesis utilizando bases antagonistas de mmp-9 y/o integrinas beta-1.
WO2001026671A1 (en) * 1999-10-12 2001-04-19 Smithkline Beecham Corporation Methods of treatment using dual matrix-metalloproteinase-2 and matrix metalloproteinase-9 inhibitors
US6573096B1 (en) * 2000-04-01 2003-06-03 The Research Foundation At State University Of New York Compositions and methods for inhibition of cancer invasion and angiogenesis
WO2001090326A2 (en) * 2000-05-22 2001-11-29 Pharmacia & Upjohn Company Novel matrix metalloproteinases
AR028606A1 (es) 2000-05-24 2003-05-14 Smithkline Beecham Corp Nuevos inhibidores de mmp-2/mmp-9
PE20020132A1 (es) * 2000-06-29 2002-03-04 Abbott Lab Anticuerpos de especificidad doble y metodos para la elaboracion y el uso de los mismos
US20070258987A1 (en) 2000-11-28 2007-11-08 Seattle Genetics, Inc. Recombinant Anti-Cd30 Antibodies and Uses Thereof
AU2002235692A1 (en) * 2001-02-23 2002-09-04 Biophage Inc. Methods and compositions for preventing and treating neutrophil-mediated diseases
EP1322957B1 (en) 2001-05-04 2009-08-12 Biosite Incorporated Diagnostic markers of acute coronary syndromes and methods of use thereof
AU2003274059A1 (en) * 2002-10-23 2004-05-13 F. Hoffmann-La Roche Ag Combination of a trioxopyrimidine compound inhibitor and an anti-tumor agent, and uses thereof
ATE517926T1 (de) * 2003-04-04 2011-08-15 Yeda Res & Dev Antikörper zur hemmung der aktivität von mmp-2 und mmp-9
US7435800B2 (en) 2003-05-23 2008-10-14 Chi-Mei Medical Center Antibodies to interleukin-20 and method for inhibiting interleukin-20 induced cell proliferation
US20050118632A1 (en) 2003-11-06 2005-06-02 Jian Chen Polynucleotides and polypeptides encoding a novel metalloprotease, Protease-40b
CN100497324C (zh) * 2004-05-27 2009-06-10 武汉科艾硒医药科技发展有限公司 具有抗纤维化及抑制明胶酶活性的化合物及其应用
WO2006036928A2 (en) 2004-09-27 2006-04-06 Wayne State University Inhibitors of matrix metalloproteinases to treat neurological disorders
US20080254490A1 (en) 2005-02-02 2008-10-16 Ramkumar Menon Salivary Protease Assays for Identifying Increased Risk of Preterm Delivery Induced by Premature Rupture of Fetal Membranes
DE102005015040A1 (de) 2005-03-31 2006-10-05 Sanofi-Aventis Deutschland Gmbh Substituierte Tetrahydroisochinoline als MMP-Inhibitoren, Verfahren zu ihrer Herstellung und ihre Verwendung als Medikament
US20070203209A1 (en) 2005-08-18 2007-08-30 Wilmin Bartolini Useful indole compounds
US8092819B2 (en) 2006-01-27 2012-01-10 Cook Medical Technologies LLC. Implantable medical device coated with a bioactive agent
WO2007149948A2 (en) 2006-06-20 2007-12-27 The Gov. Of The Usa As Represented By The Secretary Of The Department Of Health And Human Services Compositions and methods for diagnosis and treatment of tumors
EP2155691B1 (en) * 2007-02-23 2016-01-13 Yeda Research and Development Co. Ltd. Antibodies and pharmaceutical compositions containing same useful for inhibiting activity of metalloproteins
WO2009079581A1 (en) 2007-12-17 2009-06-25 Dyax Corp. Evaluating mmp expression in patient stratification and other therapeutic, diagnostic and prognostic methods for cancer
CA2707637A1 (en) 2007-12-17 2009-06-25 Dyax Corp. Compositions and methods for treating osteolytic disorders comprising mmp-14 binding proteins
US8013125B2 (en) 2008-03-03 2011-09-06 Dyax Corp. Metalloproteinase 9 and metalloproteinase 2 binding proteins
JP2011517662A (ja) 2008-03-03 2011-06-16 ダイアックス コーポレーション メタロプロテアーゼ9結合タンパク質
WO2010045388A2 (en) 2008-10-14 2010-04-22 Dyax Corp. Use of mmp-9 and mmp-12 binding proteins for the treatment and prevention of systemic sclerosis
WO2010048432A1 (en) 2008-10-22 2010-04-29 Dyax Corp. Combination treatments comprising protease binding proteins for inflammatory disorders
WO2011028883A2 (en) 2009-09-03 2011-03-10 Dyax Corp. Metalloproteinase 9 and metalloproteinase 2 binding proteins

Similar Documents

Publication Publication Date Title
US8013125B2 (en) Metalloproteinase 9 and metalloproteinase 2 binding proteins
US8008445B2 (en) Metalloproteinase 9 binding proteins
JP2011517662A5 (enExample)
US8114968B2 (en) Metalloproteinase-12 specific monoclonal antibody
US20110135573A1 (en) Metalloproteinase 9 and metalloproteinase 2 binding proteins
JP6660294B2 (ja) 活性化可能抗体を結合するための組成物及び方法
JP6333882B2 (ja) 抗体−薬剤コンジュゲート
JP2023159314A (ja) マトリプターゼ及びu‐プラスミノーゲン活性化因子の基質及び他の切断可能部分、並びにその使用方法
DK2521568T3 (en) PLASMACALLIC CLEANING PROTEINS
US20220267455A1 (en) Anti-il1rap antibodies and antibody drug conjugates
CN113271956A (zh) 基质金属蛋白酶可裂解的和丝氨酸或半胱氨酸蛋白酶可裂解的底物及其使用方法
CA2635588C (en) Metalloproteinase binding proteins
AU2018300237A1 (en) Anti-CD166 antibodies and uses thereof
WO2009097397A2 (en) Metalloproteinase binding proteins
CN110078827A (zh) 结合表皮生长因子受体的可活化的抗体其使用方法
JP2016538240A (ja) マトリックスメタロプロテイナーゼ基質及び他の切断可能部分並びにそれらの使用方法
WO2010045388A2 (en) Use of mmp-9 and mmp-12 binding proteins for the treatment and prevention of systemic sclerosis
US20130156784A1 (en) Compositions Using Antibodies Directed To GPNMB And Uses Thereof
AU2019204295A1 (en) Plasma kallikrein binding proteins